Bulevirtide: First Approval
online resource
posted on 2020-09-18, 00:21 authored by Connie KangEthics Declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
Connie Kang and Yahiya Y. Syed are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information about this Adis Drug Review can be found here.
Abstract
Bulevirtide
(Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the
treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus
(HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment
of chronic HDV infection in HDV RNA positive adult patients
with compensated liver disease. This
article summarizes the milestones in the development of bulevirtide leading to
this first approval for chronic HDV.
© Springer Nature Switzerland AG 2020
